Recombinant phages
CA 2244792 A1 · Owner: Mardh, Sven · Inventors: Mardh, Sven
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to bacteriophages for use in the treatment or prophylaxis of bacterial infections, especially mucosal bacterial infections such as Helicobacter pylori infections. In particular it relates to modified , filamentous bacteriophages e.g. M13 phages, for such use, which , bacteriophages present at its surface a recombinant protein comprising: (i) a first component derived from a bacteriophage surface protein; and (ii) a second component comprising variable region sequences of an antibody to provide a bacterial antigen binding site said second component rendering said , bacteriophage capable of binding to and thereby inhibiting growth of bacterial cells …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 5, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 5, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 5, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.